Kurs
-1,43%
Likviditet
0,58 MNOK
Kalender
| Tid* | ||
| 2025-04-24 | - | Årsstämma |
| 2025-02-26 | 07:00 | Bokslutskommuniké 2024 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2024-04-11 | - | Årsstämma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2023-04-26 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-03-01 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | 15-10 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-28 | - | Årsstämma |
| 2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2021-03-22 | - | Extra Bolagsstämma 2021 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-21 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-06-10 | - | Årsstämma |
| 2020-05-26 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2019-04-25 | - | Årsstämma |
| 2019-02-18 | - | Extra Bolagsstämma 2019 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2018-05-30 | - | Årsstämma |
| 2018-05-30 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-12-20 | - | Extra Bolagsstämma 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-23 | - | Kvartalsrapport 2016-Q3 |
| 2016-10-12 | - | Extra Bolagsstämma 2016 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-31 | - | Kapitalmarknadsdag 2016 |
| 2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2016-05-19 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-17 | - | Kapitalmarknadsdag 2015 |
| 2015-10-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-27 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-09 | - | Årsstämma |
| 2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Oslo, 17 August 2023: Thor Medical ASA will release its first half results on Thursday 31 August 2023 at 07:00 am (CEST).
A presentation of the results followed by a Q&A session will be held on the same day at 08:00 am at Carnegie's offices at Aker Brygge, Fjordalleen 16, and through a live webcast. The presentation and the Q&A session can be followed through a live webcast from our website www.thormedical.no or Thor Medical webcast Q2 2023 (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230831_5).
For further information, please contact:
Brede Ellingsæter, CFO, brede.ellingseter@thormedical.no (https://connect-eu.notified.com/Tracker?data=OsuHNo5gZJuKSkeUd6Iq_qGQafBfHnF0_z2qp0-WfFBtsaNKIQVO47szyCsf6BrutM7x7LAp5WYebh1Y1B-OdQ0jSpzaXPOhB32gG015eDdequxTTjDdK6O3OzOaKgH_000277396724)
Ludvik Sandnes, Chair of the Board, lsandnes@nordicnanovector.com (https://connect-eu.notified.com/Tracker?data=RO9FggVXbDLhi1Ze1lSzNNTs6BirijrTBb5LFo829WG1I3D85MuJvEcmJ51zJxkf6GLdfAdPIjVFc6zkhhMTLGUPyhOrCIdueEAWjcs-3LkIh2JEfoBKTbvLmvv3l26M000277396724)
About Thor Medical
Thor Medical is an emerging supplier of radionuclides, alpha particle emitters, for medical use in cancer therapy. Thor Medical has developed a proprietary technology for the manufacturing of alpha particle emitters from natural resources. Its novel production process requires no irradiation in nuclear reactors, and provides reliable, environmentally friendly supply of radionuclides for the radiopharmaceutical industry. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol `TRMED'. To learn more, visit www.thormedical.no.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act